A placebo-controlled, dose-finding, phase II trial testing the efficacy and safety of BG00012, an oral formulation of dimethyl fumarate, reports a reduced incidence of gadolinium-enhancing lesions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback